Education
About Us
Working with TipRanks
Follow Us
Cytek Biosciences (CTKB)
NASDAQ:CTKB
CTKB Analyst Ratings
Hold
1 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CTKB Stock 12 Month Forecast
Average Price Target
$5.13
▲(26.98% Upside)
| Highest Price Target$8.00 | Average Price Target$5.13 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$4→$4.5
Hold
11.39%
Upside
Reiterated
08/14/25
Piper Sandler
$8
Buy
98.02%
Upside
Reiterated
08/11/25
Yuko Oku
Morgan StanleyNot Ranked
Morgan Stanley
$7→$4
Hold
-0.99%
Downside
Reiterated
08/11/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (NASDAQ: CTKB), Natera (NASDAQ: NTRA) and Warby Parker (NYSE: WRBY)We continue to have high conviction in CTKB’s higher-plexing capabilities, platform ease of use, and competitive cost structure. We also see ample runway for FSP platform growth through share gains as competitor systems near replacement cycle, especially following the launch of the upgraded among other upcoming products. Cytek Cloud also continues to demonstrate strong workflow enablement, supporting increased adoption and utilization of the FSP platform. That said, given CTKB’s instrument-heavy revenue mix (~62% of our 2025 estimates) and a 2H-weighted revenue cadence, we believe upside to near-term estimates is limited. Ultimately, we view the key drivers as: 1) accelerated installed base growth vs. our model, 2) scaling of recurring revenue to rebalance the capex- heavy mix, and 3) execution through a challenging macro environment.
TD Cowen
$4
Hold
-0.99%
Downside
Reiterated
08/06/25
Stephens
$6→$4
Buy
-0.99%
Downside
Reiterated
05/16/25
Goldman Sachs
$5.25→$4.5
Sell
11.39%
Upside
Reiterated
03/03/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$4→$4.5
Hold
11.39%
Upside
Reiterated
08/14/25
Piper Sandler
$8
Buy
98.02%
Upside
Reiterated
08/11/25
Yuko Oku
Morgan StanleyNot Ranked
Morgan Stanley
$7→$4
Hold
-0.99%
Downside
Reiterated
08/11/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (NASDAQ: CTKB), Natera (NASDAQ: NTRA) and Warby Parker (NYSE: WRBY)We continue to have high conviction in CTKB’s higher-plexing capabilities, platform ease of use, and competitive cost structure. We also see ample runway for FSP platform growth through share gains as competitor systems near replacement cycle, especially following the launch of the upgraded among other upcoming products. Cytek Cloud also continues to demonstrate strong workflow enablement, supporting increased adoption and utilization of the FSP platform. That said, given CTKB’s instrument-heavy revenue mix (~62% of our 2025 estimates) and a 2H-weighted revenue cadence, we believe upside to near-term estimates is limited. Ultimately, we view the key drivers as: 1) accelerated installed base growth vs. our model, 2) scaling of recurring revenue to rebalance the capex- heavy mix, and 3) execution through a challenging macro environment.
TD Cowen
$4
Hold
-0.99%
Downside
Reiterated
08/06/25
Stephens
$6→$4
Buy
-0.99%
Downside
Reiterated
05/16/25
Goldman Sachs
$5.25→$4.5
Sell
11.39%
Upside
Reiterated
03/03/25
Best Analysts Covering Cytek Biosciences
1 Month
xxx
Success Rate
7/25 ratings generated profit
Average Return
-2.78%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 28.00% of your transactions generating a profit, with an average return of -2.78% per trade.
3 Months
xxx
Success Rate
10/25 ratings generated profit
Average Return
-0.52%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -0.52% per trade.
1 Year
Success Rate
4/25 ratings generated profit
Average Return
-21.32%
reiterated a buy rating 11 days ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 16.00% of your transactions generating a profit, with an average return of -21.32% per trade.
2 Years
xxx
Success Rate
2/25 ratings generated profit
Average Return
-32.13%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 8.00% of your transactions generating a profit, with an average return of -32.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CTKB Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
5
5
4
2
2
Buy
0
1
1
1
0
Hold
3
7
9
13
13
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
9
14
14
16
15
Each month's total comprises the sum of three months' worth of ratings.
CTKB Financial Forecast
CTKB Stock Forecast FAQ
What is CTKB’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytek Biosciences’s 12-month average price target is 5.13.
What is CTKB’s upside potential, based on the analysts’ average price target?
Cytek Biosciences has 26.98% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CTKB a Buy, Sell or Hold?
Cytek Biosciences has a consensus rating of Hold which is based on 1 buy ratings, 3 hold ratings and 0 sell ratings.
What is Cytek Biosciences’s price target?
The average price target for Cytek Biosciences is 5.13. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $4.00. The average price target represents 26.98% Increase from the current price of $4.04.
The highest analyst price target is $8.00 ,the lowest forecast is $4.00. The average price target represents 26.98% Increase from the current price of $4.04.
What do analysts say about Cytek Biosciences?
Cytek Biosciences’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of CTKB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.